Treating kidney disease GLP-1s show higher risk than SGLT2 inhibitors in kidney outcomes, but lower albuminuria and mortality rates.

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out.

GLP-1 receptor agonists, originally developed for type 2 diabetes, are now witnessing soaring demand for weight management, with drugs like Ozempic gaining widespread popularity, particularly on ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity … ...

The study found that the perceived effectiveness of Ozempic for weight loss is the primary driver of patient satisfaction and intent to continue treatment, even when experiencing side effects.

Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

McDonald’s has become the latest fast food chain to try to adapt to the rise of Americans on weight-loss drugs — and is teasing new, protein-rich menu items. At such a critical moment in US history, ...

Novo Nordisk stock experienced a sharp decline after disappointing 2025 results and 2026 outlook but has seen a bounce back since. Click to read my NVO update.

Weight loss drugs can be life changing but are not without risks,' says Dr Vishnu Radhakrishnan as he explains the truth ...

Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other addictions. This is a stunning gut-brain breakthrough.

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

With high price tags and undesirable side effects, people are increasingly looking for GLP-1 alternatives, and one supplement, dubbed 'nature's Ozempic,' has taken the market by storm.